Radioactive seed implantation is becoming more and more popular in the treatment of localised prostate cancer, since it is a minimally invasive approach with high cure rates. However, as more centres start to perform this therapy, possible problems and pitfalls need to be evaluated. The aim of the present study was to observe the in¯uence of seed implantation on the prostate volume and postoperative dose distribution.
Method
Forty ®ve patients with clinically localised prostate carcinomas were treated with perineal iodine-125 (I-125) seed implantation between July 1998 and April 1999. Patient age ranged from 62 ± 88 y with a mean of 71.8 y. Before seed implantation a volume study was performed with transrectal ultrasound (TRUS), and the TRUS images were transferred into a computerised 3-D planning system to plan the number and location of the individual seeds. Two to three days and 6 weeks after the implantation, CT-scans (CT-1 and CT-2) of the prostate were performed to evaluate the volume changes of the prostate and the dosimetry.
Results
Mean preoperative prostate volume was 36.25 AE 1.84 cm 3 . As a result of the treatment, the prostate volume increased two days after the implantation (CT-1) by 61.45% (range 8.6 ± 205.8%) to 55.79 AE 2.48 cm 3 compared to the pre-operative TRUS-study. After 6 weeks (CT-2), the mean prostate volume decreased again to 49.3 AE 2.78 cm 3 ; however it was still 42.73% (range 65.94 ± 202.65%) higher than before the seed implantation. As a result of the volume increase, the dose distribution in the prostate decreased compared to the preoperatively planned dose: 91.04 AE 1.02% (range 74.93 ± 99.81%) of the prostate received at least the prescribed dose of 140 Gy (TG43) (based on the TRUS-study). As a result of prostate swelling, the dose distribution in CT-1 decreased to 59.9 AE 2.99% (range 12.3 ± 92.67%) and increased again by 11.08% in CT-2 to 70.98 AE 2.68%.
Conclusion
Interstitial low dose rate brachytherapy with I-125 seeds results in a fast and signi®cant prostate swelling by 61% after 2 days which is accompanied by a decrease in dose distribution up to 31%. Although the prostate volume decreased again, it was still 42.7% higher than before the implantation, resulting in a 20% decreased dose distribution. Therefore it has to be remembered that seed implantation results in prostate swelling and probably temporary underdosing. This might be less of a problem with I-125, which has a longer half-life of 60 days, but should be kept in mind with palladium-103, which only has a half-life of 17 days and a higher dose rate. In this case, the possible reduced dose distribution should be factored in, as early as the pre-planning stage.
